These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24943672)

  • 1. Prediction of response to interferon therapy in multiple sclerosis.
    Sellebjerg F; Søndergaard HB; Koch-Henriksen N; Sørensen PS; Oturai AB
    Acta Neurol Scand; 2014 Oct; 130(4):268-75. PubMed ID: 24943672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican 5 is an interferon-beta response gene: a replication study.
    Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
    Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of chosen SNVs in GPC5, CD58 and IRF8 genes in multiple sclerosis patients.
    Chorąży M; Wawrusiewicz-Kurylonek N; Posmyk R; Zajkowska A; Kapica-Topczewska K; Krętowski AJ; Kochanowicz J; Kułakowska A
    Adv Med Sci; 2019 Sep; 64(2):230-234. PubMed ID: 30818222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.
    Vosslamber S; van der Voort LF; van den Elskamp IJ; Heijmans R; Aubin C; Uitdehaag BM; Crusius JB; van der Pouw Kraan TC; Comabella M; Montalban X; Hafler DA; De Jager PL; Killestein J; Polman CH; Verweij CL
    Genes Immun; 2011 Sep; 12(6):466-72. PubMed ID: 21471993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection.
    Vandenbroeck K; Alloza I; Swaminathan B; Antigüedad A; Otaegui D; Olascoaga J; Barcina MG; de las Heras V; Bartolomé M; Fernández-Arquero M; Arroyo R; Alvarez-Lafuente R; Cénit MC; Urcelay E
    Genes Immun; 2011 Jan; 12(1):40-5. PubMed ID: 20861862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.
    Jazireian P; Sasani ST; Assarzadegan F; Azimian M
    Mol Biol Rep; 2020 Dec; 47(12):9659-9665. PubMed ID: 33269432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
    Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
    J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
    Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
    Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.
    Drulovic J; Kostic J; Mesaros S; Dujmovic Basuroski I; Stojsavljevic N; Kisic-Tepavcevic D; Pekmezovic T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S65-9. PubMed ID: 24321159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating effects of WT1 on interferon-β-vitamin D association in MS.
    Lin R; Taylor BV; Charlesworth J; van der Mei I; Blizzard L; Stewart N; Ponsonby AL; Dwyer T; Pittas F; Simpson S
    Acta Neurol Scand; 2015 Apr; 131(4):231-9. PubMed ID: 25312909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.